Literature DB >> 26076063

NF1 Mutations Are Common in Desmoplastic Melanoma.

Thomas Wiesner1, Maija Kiuru, Sasinya N Scott, Maria Arcila, Allan C Halpern, Travis Hollmann, Michael F Berger, Klaus J Busam.   

Abstract

Desmoplastic melanoma (DM) is a rare variant of melanoma with distinct clinical, histopathologic, and immunohistochemical features. Clinically, DM differs from conventional melanoma by a higher propensity for local recurrence and less frequent metastatic spread to regional lymph nodes. In its pure form, DM has a distinct appearance displaying a low density of fusiform melanocytes in a collagen-rich matrix. Whereas a number of mutations have been identified in primary melanoma, including BRAF, NRAS, GNAQ, GNA11, and KIT, and the occurrence of these mutations has been found to correlate to some extent with the histopathologic features, anatomic site, and/or mode of sun exposure, no distinct set of mutations has so far been reported for DM. To study the potential association of neurofibromin (NF1) mutations with DM, we examined 15 desmoplastic and 20 non-DMs by next-generation sequencing. Mutations of the NF1 gene were found in 14 of 15 (93%) DMs and 4 of 20 (20%) non-DMs. The high frequency of NF1 mutations in DMs suggests an important role for NF1 in the biology of this type of melanoma.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26076063      PMCID: PMC5037960          DOI: 10.1097/PAS.0000000000000451

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  39 in total

1.  Desmoplastic malignant melanoma (a rare variant of spindle cell melanoma).

Authors:  J Conley; R Lattes; W Orr
Journal:  Cancer       Date:  1971-10       Impact factor: 6.860

2.  Unexpected extradermatological findings in 31 patients with xeroderma pigmentosum type C.

Authors:  S Hadj-Rabia; D Oriot; N Soufir; H Dufresne; E Bourrat; S Mallet; N Poulhalon; K Ezzedine; E Ezzedine; B Grandchamp; A Taïeb; B Catteau; A Sarasin; C Bodemer
Journal:  Br J Dermatol       Date:  2013-05       Impact factor: 9.302

3.  SOX10 expression distinguishes desmoplastic melanoma from its histologic mimics.

Authors:  Beth Palla; Albert Su; Scott Binder; Sarah Dry
Journal:  Am J Dermatopathol       Date:  2013-07       Impact factor: 1.533

4.  Allelic loss at the neurofibromatosis type 1 (NF1) gene locus is frequent in desmoplastic neurotropic melanoma.

Authors:  R Gutzmer; R A Herbst; S Mommert; P Kiehl; F Matiaske; A Rütten; A Kapp; J Weiss
Journal:  Hum Genet       Date:  2000-10       Impact factor: 4.132

5.  Clinical and dermoscopic characteristics of desmoplastic melanomas.

Authors:  Natalia Jaimes; Lucy Chen; Stephen W Dusza; Cristina Carrera; Susana Puig; Luc Thomas; John W Kelly; Lucy Dang; Iris Zalaudek; Ralph P Braun; Scott W Menzies; Klaus J Busam; Ashfaq A Marghoob
Journal:  JAMA Dermatol       Date:  2013-04       Impact factor: 10.282

6.  Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms.

Authors:  David E Reuss; Antje Habel; Christian Hagenlocher; Jana Mucha; Ulrike Ackermann; Claudia Tessmer; Jochen Meyer; David Capper; Gerhard Moldenhauer; Victor Mautner; Pierre-Olivier Frappart; Jens Schittenhelm; Christian Hartmann; Christian Hagel; Kathrin Katenkamp; Iver Petersen; Gunhild Mechtersheimer; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2014-01-25       Impact factor: 17.088

7.  Germline and somatic NF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNSTs).

Authors:  M Upadhyaya; Lan Kluwe; G Spurlock; Bisma Monem; E Majounie; K Mantripragada; Martino Ruggieri; N Chuzhanova; D G Evans; R Ferner; N Thomas; A Guha; V Mautner
Journal:  Hum Mutat       Date:  2008-01       Impact factor: 4.878

8.  Differential expression of S100 protein subtypes in malignant melanoma, and benign and malignant peripheral nerve sheath tumors.

Authors:  Daisuke Nonaka; Luis Chiriboga; Brian P Rubin
Journal:  J Cutan Pathol       Date:  2008-06-10       Impact factor: 1.587

Review 9.  Desmoplastic melanoma: a review.

Authors:  Lucy L Chen; Natalia Jaimes; Christopher A Barker; Klaus J Busam; Ashfaq A Marghoob
Journal:  J Am Acad Dermatol       Date:  2012-12-23       Impact factor: 11.527

10.  An integrated map of genetic variation from 1,092 human genomes.

Authors:  Goncalo R Abecasis; Adam Auton; Lisa D Brooks; Mark A DePristo; Richard M Durbin; Robert E Handsaker; Hyun Min Kang; Gabor T Marth; Gil A McVean
Journal:  Nature       Date:  2012-11-01       Impact factor: 49.962

View more
  24 in total

Review 1.  The NF1 somatic mutational landscape in sporadic human cancers.

Authors:  Charlotte Philpott; Hannah Tovell; Ian M Frayling; David N Cooper; Meena Upadhyaya
Journal:  Hum Genomics       Date:  2017-06-21       Impact factor: 4.639

2.  Nano-puerarin regulates tumor microenvironment and facilitates chemo- and immunotherapy in murine triple negative breast cancer model.

Authors:  Huan Xu; Mengying Hu; Mengrui Liu; Sai An; Kaiyun Guan; Menglin Wang; Lei Li; Jing Zhang; Jun Li; Leaf Huang
Journal:  Biomaterials       Date:  2020-01-17       Impact factor: 12.479

3.  Identification of recurrent mutational events in anorectal melanoma.

Authors:  Hui Min Yang; Susan J Hsiao; David F Schaeffer; Chi Lai; Helen E Remotti; David Horst; Mahesh M Mansukhani; Basil A Horst
Journal:  Mod Pathol       Date:  2016-10-14       Impact factor: 7.842

Review 4.  NRAS mutant melanoma: an overview for the clinician for melanoma management.

Authors:  Russell W Jenkins; Ryan J Sullivan
Journal:  Melanoma Manag       Date:  2016-02-17

Review 5.  The NF1 gene in tumor syndromes and melanoma.

Authors:  Maija Kiuru; Klaus J Busam
Journal:  Lab Invest       Date:  2017-01-09       Impact factor: 5.662

Review 6.  Molecular genetic and immunotherapeutic targets in metastatic melanoma.

Authors:  C Melis; A Rogiers; O Bechter; Joost J van den Oord
Journal:  Virchows Arch       Date:  2017-03-29       Impact factor: 4.064

7.  NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors.

Authors:  Carl M Thielmann; Eleftheria Chorti; Johanna Matull; Rajmohan Murali; Anne Zaremba; Georg Lodde; Philipp Jansen; Luisa Richter; Julia Kretz; Inga Möller; Antje Sucker; Rudolf Herbst; Patrick Terheyden; Jochen Utikal; Claudia Pföhler; Jens Ulrich; Alexander Kreuter; Peter Mohr; Ralf Gutzmer; Friedegund Meier; Edgar Dippel; Michael Weichenthal; Annette Paschen; Elisabeth Livingstone; Lisa Zimmer; Dirk Schadendorf; Eva Hadaschik; Selma Ugurel; Klaus G Griewank
Journal:  Eur J Cancer       Date:  2021-11-04       Impact factor: 10.002

8.  Distinguishing Neurofibroma From Desmoplastic Melanoma: The Value of p53.

Authors:  Ashley Elsensohn; Jessica Shiu; Narina Grove; Anna-Marie Hosking; Ronald Barr; Sébastien de Feraudy
Journal:  Am J Surg Pathol       Date:  2018-03       Impact factor: 6.394

Review 9.  Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy.

Authors:  Thomas Wiesner; Heinz Kutzner; Lorenzo Cerroni; Martin C Mihm; Klaus J Busam; Rajmohan Murali
Journal:  Pathology       Date:  2016-01-18       Impact factor: 5.306

Review 10.  Neurofibromin and suppression of tumorigenesis: beyond the GAP.

Authors:  Juan Mo; Stefanie L Moye; Renee M McKay; Lu Q Le
Journal:  Oncogene       Date:  2022-01-23       Impact factor: 8.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.